Results 1 to 10 of about 54,207 (313)

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies

Frontiers in Oncology, 2023
Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib.
Fang Cheng, Fang Cheng, Qiling Xu, Qiling Xu, Qiang Li, Qiang Li, Zheng Cui, Zheng Cui, Weiming Li, Fang Zeng, Fang Zeng   +10 more
doaj   +2 more sources

Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling

Frontiers in Cardiovascular Medicine, 2022
Dasatinib treatment is approved as first-line therapy for chronic myeloid leukemia. However, pulmonary hypertension (PH) is a highly morbid and often fatal side-effect of dasatinib, characterized by progressive pulmonary vascular remodeling.
Rui Wang, Rui Wang, Jinjin Pan, Jinzhen Han, Miaomiao Gong, Liang Liu, Yunlong Zhang, Ying Liu, Dingyou Wang, Qing Tang, Na Wu, Lin Wang, Jinsong Yan, Hua Li, Yuhui Yuan   +14 more
doaj   +2 more sources

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype [PDF]

BMC Cancer, 2010
Background Recent studies have suggested that the Src inhibitor dasatinib preferentially inhibits the growth of breast cancer cells of the basal-like subtype.
Watanabe Mika, Kozuka Yuji, Moriya Takuya, Kanomata Naoki, Kurebayashi Junichi, Sonoo Hiroshi   +5 more
doaj   +2 more sources

Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling

Journal of Neuroinflammation, 2019
Background The FDA-approved small-molecule drug dasatinib is currently used as a treatment for chronic myeloid leukemia (CML). However, the effects of dasatinib on microglial and/or astrocytic neuroinflammatory responses and its mechanism of action have ...
Ka-Young Ryu, Hyun-ju Lee, Hanwoong Woo, Ri-Jin Kang, Kyung-Min Han, HyunHee Park, Sang Min Lee, Ju-Young Lee, Yoo Joo Jeong, Hyun-Wook Nam, Youngpyo Nam, Hyang-Sook Hoe   +11 more
doaj   +2 more sources

Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report [PDF]

SAGE Open Medical Case Reports
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase ...
Ryan Sabour, Sohrab Kharabaf, Eric Frazier, Matthew Nguyen, Dao Le, Jonathan Zuckerman, Ramy Hanna   +6 more
doaj   +2 more sources

Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age

Aging Cell, 2023
Aging results in an elevated burden of senescent cells, senescence‐associated secretory phenotype (SASP), and tissue infiltration of immune cells contributing to chronic low‐grade inflammation and a host of age‐related diseases.
M. Islam, Eric Tuday, Shanena Allen, John Kim, Daniel W Trott, W. Holland, A. Donato, L. Lesniewski   +7 more
semanticscholar   +1 more source

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL

Journal of Clinical Oncology, 2023
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available.
R. Foà, R. Bassan, L. Elia, A. Piciocchi, S. Soddu, M. Messina, F. Ferrara, M. Lunghi, A. Mulè, M. Bonifacio, N. Fracchiolla, P. Salutari, P. Fazi, A. Guarini, A. Rambaldi, S. Chiaretti   +15 more
semanticscholar   +1 more source

New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies

Journal of Enzyme Inhibition and Medicinal Chemistry, 2023
Two new series of pyrazolyl-thiazolidinone/thiazole derivatives 16a–b and 18a–j were synthesised, merging the scaffolds of celecoxib and dasatinib. Compounds 16a, 16b and 18f inhibit COX-2 with S.I.
Wael A. A. Fadaly, Taha H. Zidan, Nesma M. Kahk, Fatma E. A. Mohamed, Marwa M. Abdelhakeem, Rehab G Khalil, M. T. Nemr   +6 more
semanticscholar   +1 more source

Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice

Nature Communications, 2021
Intervertebral disc degeneration is highly prevalent within the elderly population and is a leading cause of chronic back pain and disability. Due to the link between disc degeneration and senescence, we explored the ability of the Dasatinib and ...
E. J. Novais, V. Tran, Shira N. Johnston, K. Darris, Alex J Roupas, G. Sessions, I. Shapiro, B. Diekman, M. Risbud   +8 more
semanticscholar   +1 more source

Senolytic combination of Dasatinib and Quercetin alleviates intestinal senescence and inflammation and modulates the gut microbiome in aged mice.

The journals of gerontology. Series A, Biological sciences and medical sciences, 2021
Cellular senescence contributes to age-related disorders including physical dysfunction, disabilities and mortality caused by tissue inflammation and damage.
T. Saccon, R. Nagpal, H. Yadav, M. Cavalcante, Allancer D. C. Nunes, A. Schneider, A. Gesing, Brian Hughes, Matthew J. Yousefzadeh, T. Tchkonia, J. Kirkland, L. Niedernhofer, P. Robbins, M. Masternak   +13 more
semanticscholar   +1 more source